Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hodgkin's Lymphoma - Relapsed/Refractory”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01573000
What this trial is testing

Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Lymphoma, Non-Hodgkin
GlaxoSmithKline 78
Early research (Phase 1)Study completedNCT03985189
What this trial is testing

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Who this might be right for
Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Kyowa Kirin Co., Ltd. 14
Testing effectiveness (Phase 2)Looking for participantsNCT06563596
What this trial is testing

Epco, Zanu, Ritux for R/R FL or MZL

Who this might be right for
Follicular LymphomaLymphomaNon-Hodgkin Lymphoma+3 more
Reid Merryman, MD 71
Testing effectiveness (Phase 2)Ended earlyNCT05453396
What this trial is testing

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+5 more
University of Washington 11
Early research (Phase 1)Looking for participantsNCT06015880
What this trial is testing

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI) 30
Testing effectiveness (Phase 2)Looking for participantsNCT07123454
What this trial is testing

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
B-cell Non-Hodgkin Lymphoma
AstraZeneca 91
Early research (Phase 1)Study completedNCT00511082
What this trial is testing

Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Who this might be right for
Non-Hodgkin's Lymphoma(NHL)Multiple Myeloma
Otsuka Beijing Research Institute 7
Testing effectiveness (Phase 2)WithdrawnNCT05312476
What this trial is testing

Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Who this might be right for
Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Testing effectiveness (Phase 2)Study completedNCT00484874
What this trial is testing

Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Who this might be right for
Hodgkin's Disease
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 12
Early research (Phase 1)Study completedNCT00622258
What this trial is testing

A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Novartis Pharmaceuticals 13
Testing effectiveness (Phase 2)Looking for participantsNCT02332668
What this trial is testing

Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Who this might be right for
MelanomaLymphomaSolid Tumor+2 more
Merck Sharp & Dohme LLC 370
Early research (Phase 1)Not Yet RecruitingNCT06970496
What this trial is testing

A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.

Who this might be right for
Relapsed or Refractory B Cell Non Hodgkin Lymphoma
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. 48
Testing effectiveness (Phase 2)UnknownNCT04626908
What this trial is testing

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed and RefractoryLymphoid Hematological Malignancies
He Huang 18
Early research (Phase 1)UnknownNCT05650580
What this trial is testing

TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

Who this might be right for
Non-Hodgkin's Lymphoma, RelapsedNon-Hodgkin's Lymphoma RefractoryAdvanced Solid Tumor
Tarapeutics Science Inc. 26
Early research (Phase 1)Looking for participantsNCT05892718
What this trial is testing

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Who this might be right for
Advanced Solid TumorRefractory Non-Hodgkin Lymphoma
FBD Biologics Limited 80
Early research (Phase 1)Active Not RecruitingNCT05665062
What this trial is testing

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Who this might be right for
CLL/SLLNHLMantle Cell Lymphoma+4 more
Synthekine 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT03162536
What this trial is testing

Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Who this might be right for
Lymphoma, B-CellSmall Lymphocytic LymphomaChronic Lymphocytic Leukemia+6 more
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 190
Testing effectiveness (Phase 2)Study completedNCT03373071
What this trial is testing

Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL

Who this might be right for
CD19-ALLCD19-LNH
Bambino Gesù Hospital and Research Institute 29
Early research (Phase 1)Study completedNCT00791011
What this trial is testing

Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat

Who this might be right for
Hodgkin's LymphomaLow Grade LymphomaLymphoma+3 more
Amgen 33
Early research (Phase 1)UnknownNCT04887012
What this trial is testing

Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

Who this might be right for
B-cell Non Hodgkin Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine 25
Next Page